About Genocea

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea used ATLAS to identify the antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and to identify T cell response signatures of cancer patients treated with checkpoint blockade therapies to potentially improve clinical practice. Genocea expects GEN-003 to be ready to begin Phase 3 development and to file an Investigational New Drug (IND) application for its neoantigen cancer vaccine candidate GEN-009 by the end of 2017.

adjusted-apc-t-cell-image2

Stock Quote

NASDAQ GNCA
$6.39
+ 0.14 (+2.24%)


0.17M

Volume

$6.50

Day High

$6.16

Day Low

Apr 28, 2017 ET on 4:00 PM Delayed at least 20 minutes.

Stock Chart



Webcasts

May 4, 2017 at 9:00 AM ET